- Name: Shengping Li
- Title: Professor and Director of the Department of Pancreatobiliary Surgery
- Email: lishp@sysucc.org.cn
- Phone:
Profile
Dr. Shengping Li is currently a professor in the Department of Pancreatobiliary Surgery at Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China. He specializes in the treatment of pancreatic and biliary cancers and is a renowned surgical specialist in China. Dr. Li obtained his Doctoral degree in surgery at Sun Yat-sen University of Medical Sciences in 1998 and was a postdoctoral research fellow in The Cancer Center at the University of Michigan, USA in 2003. As the chief expert of pancreatic cancer, Dr. Li has cared for more than 3,000 patients with pancreatobiliary cancer and performs more than 400 surgeries per year, including open, laparoscopic and robot-assited pancreaticoduodenectomy (Whipple), distal pancreatectomy, total pancreaticoduodenectomy, irreversible electroporation (IRE), and radical resection of cholangiocarcinoma. Dr. Li has also designed and conducted a series of clinical trials to test novel drugs and new treatments for pancreatic cancer. His work is mainly focused on multiple disciplinary treatment of pancreatobiliary cancer and its effects on the tumor immune microenvironment, specifically, tumorigenesis, development and prognosis. He has established an international reputation in pancreatic and biliary cancers, and served as a steering committee member in several academic organizations. He has published more than 90 peer-reviewed papers, including papers in renowned journals such as Hepatology, the Journal of Hepatology, Cancer Research, Cancer Letters, Clinical translational medicine, Oncoimmunology, and Frontiers in Oncology.
Interests
Multiple disciplinary treatment, especially surgical treatment of pancreatobiliary cancer, the treatment of locally advanced pancreatic cancer with irreversible electroporation and its immune changes in the tumor microenvironment, the design and conduct of clinical trials on pancreatobiliary cancer.
Education
M.D. School of Medicine, Hengyang medical college, Nanhua University, China, 1981-1986.
Master Degree in Hepatobiliary Surgery, Sun Yat-sen University of Medical Sciences, China, 1988-1991.
Ph.D in Gastropancreatic Surgery, Sun Yat-sen University of Medical, China, 1995-1998.
Postdoctoral research Fellow, The Cancer Center of University of Michigan, USA, 2001-2003.
Publications
Selected publications
1. The T cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. He C#, Huang X#, Zhang Y#, Cai Z, Lin X, Li S*. Clinical and Translational Medicine. 2020 Jun;10(2):e39.
2. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Huang X#, He C#, Hua X#, Kan A, Mao Y, Sun S, Duan F, Wang J, Huang P, Li S*. Clinical and Translational Medicine. 2020 Jun;10(2):e41.
3. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Sun S#, Liu Y#, He C#, Hu W, Liu W, Huang X, Wu J, Xie F, Chen C, Wang J, Lin Y, Zhu W, Yan G, Cai J*, Li S*. Cancer Letters. 2021 Apr 1;502:9-24.
4. The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer, He C#; Sun S#; Zhang Y#; Xie F; Li S*; OncoImmunology, 2021, 10(1): 1-12.
5. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. He C#, Huang X#, Zhang Y#, Cai Z, Lin X, Li S*. Frontiers in Oncology. 2020 Jan 22;10:6.
6. A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. He C#, Sun S#, Zhang Y#, Lin X, Li S*. Frontiers in Oncology. 2020 Sep 3;10:1564.
7. The impact of different metastatic patterns on survival in patients with pancreatic cancer. He C#, Huang X#, Zhang Y#, Lin X, Li S*. Pancreatology. 2021 Jan 27:S1424-3903(21)00038-7.
8. Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. He C#, Wang J#, Zhang Y#, Lin X, Li S*. Pancreatology. 2020 Apr;20(3):477-484.
9. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Xu L, Wang J, Kim Y, Shuang Z, Zhang Y, Lao X, Li Y, Chen M, Pawlik T, Xia J, Li S*, Lau W. Oncoimmunology. 2016 Mar;5(3):e1083671.
10. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Shuang ZY, Wu WC, Xu J, Lin G, Liu YC, Lao XM, Zheng L, Li S*. Cancer Letters. 2014 Nov 28;354(2):320-8.
Updated March 2021 by International Office, Sun Yat-sen University Cancer Center